TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04957017

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: After the data was collected, the women in the intervention group were trained on Hand-Washing and Nutrition during the COVID-19 period. The training on hand-washing and nutrition was given using the Hand-Washing and Nutrition Training Guide prepared by the researchers, and the Hand-Washing and Nutrition Training Manual covering the content of the training, was distributed to the women at the end of the training
Study: NCT01073904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Emergency Pill (BAY86-5028)
Description: Single dose of 1.5 mg coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postinor 2
Description: Single dose of 1.5 mg tablet
Study: NCT03274635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Desk-based pedaling device and pedaling incentives provided
Description: Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
Study: NCT01249976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood culture
Description: blood culture
Study: NCT00701506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patterned Electrical Neuromuscular Stimulation
Description: * 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PENS
Description: * 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings.
Study: NCT02612363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine for sedation
Description: Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine for sedation
Description: Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose
Study: NCT02592486

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®
Description: Injections of pneumococcal vaccine and influenza vaccine simultaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sequential administration of Pneumovax NP® and Fluvic HA syringe®
Description: Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
Study: NCT01266499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin (Polymyxin E) 100mg x 4/d
Description: Colistin (Polymyxin E) 100mg x 4/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: both medications
Description: PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
Study: NCT01917409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-stylet
Description: the device is to guide the nasotracheal tube into trachea
Study: NCT01268176

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU once per month for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU once per month for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 50,000 IU once per month for 3 months
Study: NCT02267096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Treatment
Description: A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal Treatment
Description: A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
Study: NCT02337179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voluntary medical male circumcision
Description: Male Circumcision Under Local Anesthesia using the Forceps Guided Method
Study: NCT04072718

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: 34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
Study: NCT01816698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurine granule
Description: 1 package(1.6g taurine granule) once a day after meals, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 package once a day after meals, 12 weeks
Study: NCT04409366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Crown Lengthening (CCL)
Description: Using the surgical guide, submarginal internal bevel incisions were performed on the buccal aspect of the affected teeth. A full-thickness flap was raised up to the mucogingival junction (Dominguez et al., 2020). Ostectomy and osteoplasty were carried out by means of rotatory instruments and surgical chisels, as necessary, to achieve the necessary space between the bone crest and the restorative margin according to the presurgical plan. The CEJ was not the reference point since, in many cases, the position of the final margin of the restoration was planned apical to the actual position of the CEJ. Exposed root surfaces were carefully instrumented manually with curettes and, finally, vertical internal mattress sutures were placed to position the gingival margin at the level of the margin of the planned restoration. Sutures were removed after 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-stage Crown Lengthening (SCL)
Description: In the first surgical intervention, intrasulcular incisions were performed and a full thickness flap was raised up to the mucogingival junction. Ostectomy and osteoplasty were performed to establish the space for supracrestal tissue attachment, following the restorative plan and using the presurgical blueprint as the reference to determine the final position of the restoration margin, instead of the CEJ (Lee, 2004). Then the flaps were repositioned and secured with internal mattress sutures, placing the gingival margin at the original level. Sutures were removed at 7 days. In the second stage, after 3-4 months, minor gingival recontouring was performed, if necessary, to attain the desired gingival margin position according to the presurgical plan.
Study: NCT01165996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given subcutaneously

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study: NCT04701697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Albumin Injection
Description: Participants will receive Recombinant Human Albumin Injection of intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Albumin Injection
Description: Participants will receive Recombinant Human Albumin Injection of intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Albumin Injection
Description: Participants will receive Recombinant Human Albumin Injection of intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HumanAlbumin
Description: Participants will receive HumanAlbumin of intravenous infusion
Study: NCT03465371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSC OnDemand Training Intervention
Description: Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1-self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2-instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: InPerson Intervention
Description: Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual InPerson Intervention
Description: Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of virtual (via Zoom) in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of virtual (via Zoom) in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role
Study: NCT02720952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort®
Description: dry granule formulation of hydrocortisone
Study: NCT04261257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac scanner
Description: As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of patient's care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks, a transcranial doppler, a biological assessment, a 24-hour holter or long-term holter.~The additional examination, specific to the research, corresponds to a cardiac scanner, which does not require the additional injection of contrast medium, carried out during the cerebral artery scanner within 36 hours of discovering the stroke. Within 3 days after inclusion, a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care are carried out.
Study: NCT01497236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Nutrition supplement with RUTF or MNP
Description: 14 days nutritional supplementation with either~* a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~* a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~* a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Nutrition supplement with RUTF or MNP
Description: 14 days nutritional supplementation with either~* a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~* a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~* a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier
Study: NCT00938652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin
Description: Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib
Description: Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)
Study: NCT02076477

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiotherapy
Description: Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors\>3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel:60mg/m2 d1,Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel:60mg/m2 d1,Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed: 500mg/m2 d1,Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: pemetrexed: 500mg/m2 d1,Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin：25mg/m2 d1-3，Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin：25mg/m2 d1-3，Given IV
Study: NCT02710292

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Study: NCT04803448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefit statement
Description: The participant reads this statement after asked one of eight health questions~1. What is your height in inches?~2. What is your weight in pounds?~3. How many days out of the last 2 weeks did you drink alcohol?~4. How often a month do you use other substance such as marijuana, cocaine, ecstasy, or other drugs~5. How often a month do you use Rx or non-Rx medications to excessive amounts?~6. When was the last time you smoked a cigarette?~7. How many days in the last 2 weeks did you engage in more than 30 min exercise?~8. How many times did you engage in sexual activity in the last month with another individual? . The statement reads: Accurately answering this will increase the likelihood of a correct diagnosis.~An example of this with one of the 8 health questions is... What number of days in the last 2 weeks you engaged in \>30 minutes of exercise? Accurately answering this will increase the likelihood of a correct diagnosis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Statement
Description: The participant reads this statement after being asked one of eight health questions.~The statement reads: Inaccurately answering this will increase the likelihood of an incorrect diagnosis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Privacy Statement
Description: The participant reads this statement after being asked one of eight health question for example. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefit + Privacy
Description: The statement reads Accurately answering this will increase the likelihood of a correct diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk + Privacy
Description: The statement reads Inaccurately answering this will increase the likelihood of an incorrect diagnosis. We will not share or sell this personal health information with anyone. We will comply with all HIPPA regulations regarding the protection of your data.
Study: NCT02803125

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial intervention
Description: This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support group control
Description: The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
Study: NCT01746043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: 150 mg by mouth once a day for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 capsule by mouth 2 times a day for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 capsule by mouth 2 times a day for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule by mouth 2 times a day for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth 2 times a day for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg by mouth 2 times a day for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.